SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is trending following its strong quarterly performance and upbeat guidance, fueled by surging AI chip demand and a significant long-term outlook for AI revenue, prompting community discussion about its market trajectory amidst broader sector comparisons.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk is surging amid CEO Jeff Green's substantial $148 million insider share purchase and reports of early talks with OpenAI to power ChatGPT's ad sales, igniting community discussion about a potential short squeeze for the previously oversold stock.

Palladyne AI Corp. engages in the design, development, and manufacture of industrial robotic systems that augment human performance by combining human intelligence, instinct, and judgment with the strength, endurance, and precision of machines to enhance employee safety and productivity. Its products include Palldyne IQ and Palladyne Pilot. The company was founded by Fraser M. Smith and Benjamin G. Wolff in 2015 and is headquartered in Salt Lake City, UT.

Palladyne AI Corp.

Palladyne AI is trending after announcing strong earnings and robust revenue guidance, coupled with securing new defense contracts for missile propulsion and an Air Force project advancing multi-domain swarming autonomy. This news is driving intense community discussion on its potential as a disruptive force in defense AI, particularly amidst high short interest and market volatility.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending following its earnings report and conservative 2026 guidance, which has fueled investor frustration over the stock's valuation and the projected impact of the TDAPA cliff on DefenCath revenue. The community is actively debating if the announced $75 million share buyback can counter persistent short interest and management's cautious outlook, while awaiting key REZZAYO trial results and potential Medicare Advantage contract updates.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JD.com is actively debated following its latest earnings report, which detailed substantial share buybacks and a new dividend, alongside increased investments in AI and new ventures like food delivery impacting profitability. Community sentiment is sharply divided, with some emphasizing long-term value and significant cash reserves, while others express frustration over fierce competition and the stock's persistent decline.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is facing intense community debate following a recent earnings report that highlighted declining revenue and widening losses. This financial performance is fueling widespread skepticism over the company's multi-billion-dollar market capitalization and perceived slow progress within the highly speculative quantum computing sector, with many drawing comparisons to competitors like IonQ.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull ($BULL) is trending following its latest earnings report, which showcased strong revenue and user growth but stirred community debate over an initial conflicting EPS report and higher operating expenses. While many see long-term potential in its expanding user base and global strategy, concerns about profitability and ongoing dilution keep sentiment divided within the fintech space.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is trending after releasing positive Phase 2 data for HLP004, showing significant efficacy in generalized anxiety disorder patients who remained symptomatic despite existing treatments. This promising clinical outcome has sparked intense community discussion, as the stock experienced a notable decline, leading to debate over its current valuation and the broader psychedelic sector's potential.

Amprius Technologies, Inc. engages in the development, manufacture, and market lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the United States and Rest of the World geographical segments. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius Technologies is trending after reporting strong quarterly results that surpassed analyst expectations with significant revenue growth, alongside optimistic guidance for future years. The community is actively discussing its valuation and market potential in high-performance battery applications for drones, aviation, and electric vehicles, often highlighting its tangible progress compared to competitors.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is trending as CEO Greg Abel's significant personal stock purchase and the resumption of share buybacks signal strong confidence in the company's future, with the community actively debating the ongoing capital allocation strategy given its substantial cash reserves and the leadership transition.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company stated that the global REZOLVE-AD Phase 2b study included 393 patients with moderate-to-severe atopic dermatitis.</li><li>Nektar stated that patients receiving monthly and quarterly dosing regimens resulted in sustained disease control for EASI-75, EASI-90, and other indicators.</li><li>The company also noted that it observed an increase in patients who achieved EASI-100 in the 24 micrograms per kilogram dosing regimens in the monthly and quarterly time periods.</li></ul>Nektar Therapeutics Inc. (NKTR) shares rose more than 42% in Tuesday’s opening trade after the company reported positive results from its long-term atopic dermatitis trial.Nektar announced positive results from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study of its experimental drug, rezpegaldesleukin.Retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/NKTR">Nektar Therapeutics</a> trended in the ‘extremely bullish’ territory at the time of writing, with message volumes at ‘extremely high’ levels. The NKTR stock was among the top ten trending tickers on the platform.<h2 class="st-heading-2">Nektar’s Findings In The Trial</h2>The company stated that the global REZOLVE-AD Phase 2b study included 393 patients with moderate-to-severe atopic dermatitis.Nektar stated that patients receiving monthly and quarterly dosing regimens achieved sustained disease control as measured by EASI-75, EASI-90, the validated Investigator Global Assessment of Atopic Dermatitis (vIGA-AD) response, and the Itch Numerical Rating Scale (NRS) response.The company also noted an increase in patients achieving EASI-100 on the 24 micrograms per kilogram dosing regimens during the monthly and quarterly periods.EASI refers to the Eczema Area and Severity Index. It quantifies the severity and extent of eczema symptoms across body regions. EASI-75 points to a greater than or equal to 75% improvement from baseline, while EASI-90 refers to a 90% or more improvement. Similarly, EASI 100 denotes a 100% improvement over baseline.<h2 class="st-heading-2">Retail Gives A Thumbs Up</h2>One bullish user observed that “patience does pay off,” while adding that they are not selling the stock.<stembedurl>https://stocktwits.com/aristocks/message/644554531</stembedurl>Another user stated that there is nothing to “even remotely” criticize Nektar for, following the announcement of the trial results.<stembedurl>https://stocktwits.com/clarksonhockey/message/644552638</stembedurl><a href="https://stocktwits.com/symbol/NKTR">NKTR stock</a> is up 24% year-to-date and 204% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-fisv-stock-falling-today/cZbU3sOR4Yp">Why Is FISV Stock Falling Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Low-angle view of a logo on a facade at the headquarters of Nektar Therapeutics, on October 29, 2018. (Photo by Smith Collection/Gado/Getty Images)

NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results

Nektar announced positive results from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study of its experimental drug, rezpegaldesleukin.

Equity

Is Invesco RAFI US 1500 Small-Mid ETF (PRFZ) a Strong ETF Right Now?

Should Invesco RAFI US 1500 Small-Mid ETF (PRFZ) Be on Your Investing Radar?

<ul class="summary-bullets"><li>Diana said that its takeover offer provides shareholders an attractive premium value and the plans were supported by a highly confident financing letter from two leading shipping banks.&nbsp;</li><li>Diana’s CEO said that the company was disappointed that Genco’s decision took over six weeks and did not engage with Diana’s proposal.</li><li>Diana named six shipping industry experts as nominees to Genco’s new board and said it would file the necessary documents with the SEC soon.</li></ul>Diana Shipping (DSX) announced its plans to nominate six candidates to replace existing board directors at rival firm Genco Shipping &amp; Trading (GNK).The decision comes shortly after Genco’s board <a href="https://stocktwits.com/news-articles/markets/equity/diana-shipping-shares-rise-aftergenco-rejects-acquistion-offer/cmUXVg4R4IF">rejected</a> Diana's takeover offer of an all-cash deal to buy its outstanding shares for $20.60 a piece. Diana had made the proposal in November 2025, at a 15% premium.Diana, which owns about 15% of Genco, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.dianashippinginc.com/diana-shipping-inc-nominates-six-director-candidates-for-election-to-genco-shipping-amp-trading-board/?catslug=">said</a> in a statement that its takeover offer provides shareholders with an attractive premium value and the plans were supported by a highly confident financing letter from two leading shipping banks. Genco’s decision took over six weeks and did not engage with Diana’s proposal, the company said.<a href="https://stocktwits.com/symbol/DSX">Shares of DSX</a> fell 0.48% on Friday, while <a href="https://stocktwits.com/symbol/GNK/sentiment">shares of GNK</a> declined 1.76% at the time of writing.<h2 class="st-heading-2">Disappointment Over Deal Refusal</h2>Diana believes shareholders of both companies would benefit from the combination that would push for consolidation in the dry bulk carriers sector.“Our all-cash offer would realize the benefits of combining our platforms and provide Genco shareholders with immediate, certain value at a meaningful premium to historical trading levels. Given our expressed readiness to engage constructively with Genco’s Board and its advisors, we are deeply disappointed that they have completely refused to have any dialogue with us,” said Diana’s Chief Executive Officer, Semiramis Paliou.Paliou added that as Genco’s largest shareholder, the company has a “duty to act in response to the Board’s failure to properly consider our offer.” The new board would give Genco an opportunity to explore strategic alternatives, including its own takeover offer.The company has nominated Gustave Brun-Lie, an industry veteran with about 40 years of shipping industry experience; Chao Sih Hing Francois, a director of Wah Kwong; Paul Cornell, with over 35 years of energy experience; Jens Ismar, a shipping industry veteran, Viktoria Poziopoulou, an experienced shipping lawyer, and Quentin Soanes, another shipping industry veteran.Diana said that it would file the necessary documents in relation to its proposal with the U.S.Securities and Exchange Commission soon.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around DSX shares was in the ‘bullish’ territory over the past day amid ‘extremely high’ message volumes.Meanwhile, retail sentiment around GNK shares was also in the ‘bullish’ territory over the past day amid ‘high’ message volumes.Shares of DSK have lost over 17% in the past year, while shares of GNK have climbed over 35% in the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

A Marshall Islands-registered "Diana Shipping" is docked for unloading at Rugao Port in Rugao City, Jiangsu province, China, May 13, 2023. (Photo credit should read CFOTO/Future Publishing via Getty Images)

Diana Shipping Announces Plans To Replace Six Directors At Genco In Proxy Fight

Diana Shipping said that a new board would give Genco an opportunity to explore strategic alternatives, including its own takeover offer. 

<ul class="summary-bullets"><li>Diana had offered to buy all of the outstanding shares of Genco for $20.60 per share in cash.</li><li>Diana currently beneficially owns approximately 14.8% of the Genco's common stock.</li><li>Diana’s CEO said they were deeply disappointed that Genco’s Board chose to reject the proposal without any engagement.</li></ul>Diana Shipping shares rose in Tuesday’s after-market trading after its acquisition offer was rejected by the board of Genco.&nbsp;Diana said it received a letter from the Genco Board of Directors rejecting its non-binding indicative proposal to acquire all of the issued and outstanding shares of Genco common stock not already owned by Diana for $20.60 per share in cash.“We are deeply disappointed that, despite our continued willingness to enter into discussions with Genco’s Board, it instead chose to reject our proposal without any engagement with us or our advisors. In fact, Genco’s letter raised questions about the structure, value and certainty of execution that we are ready and willing to discuss if they engage with us directly,” Diana’s CEO Semiramis Paliou said.Diana said its Board is considering all its options to advance its highly compelling offer to acquire Genco.<h2 class="st-heading-2">Diana’s Offer</h2>Diana in November had sent a non-binding indicative proposal from Diana Shipping to acquire all of the outstanding shares of Genco not already owned by Diana. Diana currently beneficially owns approximately 14.8% of the Genco's common stock.&nbsp;The proposal that was initially disclosed on November 24, represented a 15% premium to the closing price of Genco’s shares on November 21, 2025.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around DSX trended in ‘neutral’ territory amid ‘high’ message volume.Meanwhile retail sentiment around GNK trended in ‘neutral’ territory amid ‘high’ message volume.&nbsp;Diana shares have fallen 5% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Diana Shipping Shares Rise After Hours– What’s With The Genco Rejection?

Diana said it has received a letter from the Genco’s Board rejecting its non-binding indicative proposal to acquire all of the issued and outstanding shares of Genco common stock not already owned by Diana.

<ul class="summary-bullets"><li>The company said that AVT03 is approved as a biosimilar to Prolia 60 mg/mL single-use pre-filled syringe and as a biosimilar to Xgeva 70 mg/mL single-use vial.</li><li>STADA will market AVT03 as Kefdensis and Zvogra, while Dr. Reddy’s will market AVT03 as Acvybra and as Xbonzy.&nbsp;</li><li>The EC approval is based on clinical studies that demonstrated equivalent pharmacokinetics and efficacy, and comparable safety and immunogenicity to the reference product, the company said.</li></ul>Alvotech (ALVO) on Monday said that the European Commission (EC) has approved AVT03 as a biosimilar to Amgen’s Prolia and Xgeva, containing the active ingredient denosumab, and used widely to manage osteoporosis.According <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/24/3193283/0/en/Alvotech-Announces-Approval-of-AVT03-a-Biosimilar-to-Prolia-and-Xgeva-denosumab-in-the-European-Economic-Area.html">to</a> Alvotech, the European denosumab market is currently valued at approximately $1.2 billion across all indications. While widely used to manage osteoporosis, it is also used to prevent skeletal-related events in patients with certain cancers. Osteoporosis is a disease in which your bones become weak and are more prone to fracture due to a decrease in bone mineral density and bone mass.<h2 class="st-heading-2">EC Approval</h2>The company said that AVT03 is approved as a biosimilar to Prolia 60 mg/mL single-use pre-filled syringe for the treatment of osteoporosis and bone loss, and as a biosimilar to Xgeva 70 mg/mL single-use vial for the prevention of skeletal-related events in adults with advanced malignancies involving bone.AVT03 will be commercialised in Europe in partnerships with STADA Arzneimittel AG and Dr. Reddy’s, the company said. &nbsp;STADA will market AVT03 as Kefdensis and Zvogra, while Dr. Reddy’s will market AVT03 as Acvybra and as Xbonzy.The EC approval is based on clinical studies that demonstrated equivalent pharmacokinetics and efficacy, and comparable safety and immunogenicity to the reference product, the company said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Shares of the company traded flat in the pre-market session at the time of writing. On Stocktwits, retail sentiment around ALVO jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/ALVO">ALVO stock</a> is down 61% this year and by 57% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-blockbuster-drug-fails-to-slow-alzheimers-disease-progression-in-studies/cL5bIRrREQT">Novo Nordisk’s Blockbuster Drug Fails To Slow Alzheimer’s Disease Progression In Studies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, an Alvotech company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Alvotech’s Drug Approved In Europe As Biosimilar For Bone Disease Drug

AVT03 will be commercialised in Europe in partnerships with STADA Arzneimittel AG and Dr. Reddy’s, the company said. 

<ul class="summary-bullets"><li>Cantor Fitzgerald’s new price target on CABA represents over 1,000% potential upside to the stock’s closing price on Thursday.</li><li>The company said on Monday that data from across trials reinforce the potential of a single weight-based dose of Rese-cel to deliver durable, drug-free clinical responses across multiple autoimmune diseases.</li><li>Rese-cel is an investigational, autologous CAR-T cell therapy explicitly designed for the treatment of autoimmune diseases in rheumatology, neurology, and dermatology. &nbsp;</li></ul>Cantor Fitzgerald on Friday raised its price target on Cabaletta Bio (CABA) to $30 from $15 while keeping an ‘Overweight’ rating on the shares.The new price target represents over 1,000% potential upside to the stock’s closing price on Thursday.According to TheFly, the analyst noted that Auto-CAR-T is showing unprecedented and transformational efficacy in systemic sclerosis, and investors aren't appreciating the substantial unmet need.Scleroderma, also known as systemic sclerosis, is a group of autoimmune diseases that cause the hardening and tightening of the skin and connective tissues, and can also damage blood vessels and internal organs. It is characterized by the excessive buildup of collagen, which leads to fibrosis.<h2 class="st-heading-2">Cabaletta Presents Positive Data</h2>Cabaletta on Monday announced positive clinical data across trials evaluating Rese-cel. Rese-cel is an investigational, autologous CAR-T cell therapy explicitly designed for the treatment of autoimmune diseases in rheumatology, neurology, and dermatology. It is administered as a single, weight-based infusion to reset the immune system and achieve durable clinical responses without the need for chronic therapy.The company said that the data from the trials reinforce the potential of a single weight-based dose of Rese-cel to deliver durable, drug-free clinical responses across multiple autoimmune diseases.“We look forward to initiating the myositis registrational trial and anticipate alignment with FDA on the designs for lupus and systemic sclerosis this year,” said David J. Chang, Chief Medical Officer of Cabaletta, on Monday.While Myositis is a group of rare conditions characterized by muscle inflammation, Lupus is a chronic autoimmune disease where the body's immune system mistakenly attacks healthy tissues.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CABA">CABA stock</a> stayed within the ‘neutral’ territory over the past 24 hours, while message volume fell from ‘high’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:621/60;" src="data:image/png;base64,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" width="621" height="60" alt="CABA's Sentiment Meter and Message Volume as of 12:19 p.m. ET on Oct. 31, 2025 | Source: Stocktwits"><figcaption>CABA's Sentiment Meter and Message Volume as of 12:19 p.m. ET on Oct. 31, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects the company’s pipeline to generate substantial revenue in six years.<stembedurl>https://stocktwits.com/Bronco6970/message/634482351</stembedurl>CABA stock is up by 46% this year but has dropped 7% over the past 12 months. &nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/pony-ai-stock-flips-between-gains-and-losses-after-key-shenzhen-permit/cLGqPQKR3U6">Pony AI Stock Flips Between Gains And Losses After Key Shenzhen Permit: Retail Expects Shares ‘Will Run Up In The Future’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Cabaletta Bio logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why Does Cantor Fitzgerald See Over 1,000% Potential Upside For Cabaletta Bio Stock?

The analyst noted that Auto-CAR-T is showing unprecedented and transformational efficacy in systemic sclerosis, and investors aren't appreciating the substantial unmet need this represents. 

Tilray Brands, Inc. faces a regulatory reckoning: regain Nasdaq’s minimum bid price requirements soon or possibly get delisted from the exchange.&nbsp;The retail trading community on Stocktwits believes the cannabis and beer company will soon overcome this hurdle.Leamington, Canada-based Tilray received a non-compliance notice from Nasdaq on Tuesday after its stock failed to maintain the exchange’s $1 minimum closing bid price requirement for 30 consecutive business days.Shares of Tilray have lost more than half their value this year, as cannabis-linked stocks continue to struggle amid stalled federal legalization efforts.The company has 180 calendar days to meet Nasdaq's minimum bid price rule. Its stock must close at or above $1.00 per share for at least 10 consecutive business days before Sept. 21.If the company fails, it may transfer to the Nasdaq Capital Market for another 180-day extension — provided it meets other listing requirements and notifies Nasdaq of its plan to fix the issue, possibly through a reverse stock split.&nbsp;If Nasdaq still determines the company cannot regain compliance, its stock will face delisting.On Stocktwits, sentiment for Tilray ended on a slightly higher ‘bullish’ level on Wednesday amid a 45% jump in message volume.<figure class="image"><img style="aspect-ratio:1318/302;" src="https://news.stocktwits-cdn.com/TLRY_sentiment_and_message_volume_as_of_Macrh_26_png_785b929906.webp" alt="TLRY sentiment and message volume as of Macrh 26.png" width="1318" height="302"><figcaption>TLRY sentiment and message volume as of Macrh 26. | source: Stocktwits</figcaption></figure>One user expressed hopes of Nasdaq being lenient with its process and said there were “zero” delisting fears because, with the extension, Tilray has until April 2026 to regain compliance.<stembedurl>https://stocktwits.com/Finance88/message/609341203</stembedurl>Another user said the company is “vertically scaled to be dominant from flower to drinks to pharma,” pointing to its products being available on the multinational supermarket chain Whole Foods, which is owned by Amazon.com.<stembedurl>https://stocktwits.com/Heb1972/message/609362664</stembedurl>Several retail investors on Stocktwits hope Tilray does not resort to a reverse stock split.<stembedurl>https://stocktwits.com/Rs1015/message/609258289</stembedurl>In January, Tilray’s stock was dealt a blow after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tlry-stock-slides-after-q2-2025-results/chGWAd2RZD">reported</a> disappointing quarterly results and projected a $20 million revenue blow for 2025 from cutting back on certain alcohol beverage brands.Meanwhile, the company said Wednesday that the Massachusetts Superior Court dismissed a lawsuit filed by a shareholder against the company and its subsidiary Hexo.The plaintiff claimed Tilray failed to inform shareholders about Hexo’s corporate actions in late 2022 and its 2023 acquisition, allegedly causing financial losses. He sought nearly $8 million in damages.&nbsp;According to Koyfin data, short interest on Tilray has shot up from 12.7% at the start of the year to 17.3% as of the last week.The stock trades at a significant 180% discount to Wall Street’s average price target of $1.83. Out of 13 analysts covering it, nine rate it ‘hold’ and four ‘buy.’For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of a Canadian pharmaceutical and cannabis company, Tilray, is seen on a smartphone and a PC screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Tilray Retail Bulls See Nasdaq Compliance On The Horizon, Shareholder Lawsuit Victory Adds Cheer

The company has 180 calendar days to meet Nasdaq's minimum bid price rule. Its stock must close at or above $1.00 per share for at least 10 consecutive business days before Sept. 21.

Current Price	$48.55
Prev Close	$48.10
Open	$48.34
Dividend Yield	N/A
50-Day Moving Average	$48.12
Beta	N/A
Avg. Volume	109,589.03
PE Ratio	N/A

52-Week High	$50.09
52-Week Low	$32.53
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

PRFZ
Invesco FTSE RAFI US 1500 Small-Mid ETF

Feed

News

Sentiment

Fundamentals

Info

Latest PRFZ News

PRFZInvesco FTSE RAFI US 1500 Small-Mid ETF